Introduction {#s1}
============

Breast cancer accounts for the largest proportion of women's mortality worldwide ([@B44]). In the United States, approximately 12% of women will develop invasive breast cancer during their lifetime. The diagnosis of at least 276,480 new cases of invasive breast cancer and 42,170 breast cancer associated deaths are estimated in 2020 ([@B18]). It is a complicated disease with inter- and intra-tumoral heterogeneity, and there are several different classifications of breast cancer according to advanced technical methods, including histological stratification and gene expression clustering ([@B89]; [@B62]; [@B108]). The different molecular types of breast cancer correspond to different molecular mechanisms and require specific therapeutic strategies ([@B79]; [@B7]). Therefore, appropriate management and therapies are necessary to achieve the best response to improve the prognosis and survival of patients. Notably, breast cancer cells have the potential to metastasize to distant organs such as the brain, lung, liver, and bone ([@B51]; [@B53]; [@B77]; [@B114]). Cancer metastasis is a complex, multi-step process that is closely associated with cells' local invasion, blood and lymphatic diffusion, and extravasation and colonization at distant sites. Metastatic cancer cells degrade the extracellular matrix, detach from their original location, and enter the circulation system through which they reach and colonize distant organs ([@B66]; [@B64]). Metastasis is the direct cause of death from cancer, accounting for nearly 90% of deaths related to breast cancer ([@B98]). Thus, there is an urgent need to identify the underlying molecular mechanisms of breast cancer and develop effective therapeutic strategies.

Voltage-gated sodium channels (VGSCs) are primarily expressed in excitable cells such as neurons. Na^+^ influx regulated by VGSCs produces action potential and propagates excitability. VGSCs also exist in non-excitable cells, including microglia, astrocytes, immune cells, fibroblasts, and cancer cells, where they regulate and influence an array of biological functions such as phagocytosis, motility, Na^+^/K^+^-ATPase activity, and metastatic activity ([@B13]). VGSCs are composed of pore-forming α subunits and auxiliary β subunits ([@B52]). The family Nav1 comprises nine genes (*SCN1A*-*5A*, *SCN8A*-*11A*) that encode α subunits, Nav1.1 to Nav1.9. Each α subunit comprises four homologous domains, and each domain consists of six transmembrane segments ([@B22]). Five β subunits, including β1 and its splice variants β1B and β2--β4, are encoded by four genes (*SCN1B*-*SCN4B*) ([@B16]). These β subunits have been found to modulate the bioelectrical characteristics of α subunits and function as cellular adhesion molecules. Both α and β subunits play a critical role in the development of the central nervous system (CNS), and altering the expression of specific subunits may cause developmental aberrations and CNS lesions. Furthermore, expression of α and β subunits is upregulated in various cancers such as breast cancer, prostate cancer, lung cancer, and cervical cancer, observed both in *in vitro* and *in vivo* systems. They are found to enhance metastasis progression, including invasion, migration, endocytosis, and gene expression, *via* the Na^+^ currents carried by α subunits and the adhesion interaction regulated by β subunits ([@B104]). The correlation between VGSCs-inhibiting drug uses and outcomes of cancer patients has been highlighted recently ([@B35]; [@B82]; [@B57]), even though the conclusions are still inconsistent. Hence, randomized controlled trials are required to exclude confounding factors and obtain a convincing conclusion in the future.

Nav1.5, a pore-forming α subunit of VGSC encoded by *SCN5A*, is expressed in lymphoma, neuroblastoma, breast and prostate cancer cells. Aberrant expression and activity of Nav1.5 are associated with cardiac excitability diseases such as arrhythmic dilated cardiomyopathy, Brugada syndrome, and long QT syndrome ([@B6]; [@B3]; [@B41]; [@B11]). Nav1.5 is also overexpressed in metastatic breast cancer *in vitro* and *in vivo* and mainly exists in its DI: S3 5′ neonatal splice form (nNav1.5) in breast cancer cells, potentiating cell metastasis ([@B67]; [@B101]). Breast cancer cells treated with specific Nav1.5 inhibitors or siRNAs show decreased motility and metastatic capacity ([@B32]).Therefore, Nav1.5 may be regarded as a promising target for the diagnosis and therapy of breast cancer.

With the high motility and metastatic capacity of breast cancer, it is imperative to determine the mechanisms of pro-metastatic effects of Nav1.5 and develop effective Nav1.5 inhibitors for breast cancer treatment. This review clarifies the role and mechanisms of Nav1.5 in metastatic breast cancer progression and summarizes some drugs with remarkable effects on reducing metastasis of breast cancer by acting on Nav1.5. All these evidence supports the idea that Nav1.5 as an anti-metastatic target for the treatment of metastatic breast cancer.

Nav1.5 Expression and Its Functional Role in Breast Cancer Metastasis {#s1_1}
---------------------------------------------------------------------

Nav1.5 in its neonatal DI:S3 5′ splice form is predominantly expressed in metastatic cancer cells ([@B37]; [@B101]). This form has been found to participate in neonatal development, while it is absent in postnatal development. The overexpression of Nav1.5 in cancer cells suggests that embryonic genes are re-expressed during ontogenesis and participate in many cellular behaviors related to metastasis ([@B68]).

The expression levels of Nav1.5 and nNav1.5 in the highly metastatic MDA-MB-231 breast cancer cell line were significantly higher than those in weakly metastatic MCF-7 cells ([@B56]; [@B111]). Nav1.5 is specifically present on the membrane of MDA-MB-231 cells, but not in normal cell lines and weakly metastatic MCF-7 cells. In breast cancers, Nav1.5 α subunit mRNA and protein expression correlates with metastatic potential, and the neonatal *SCN5A* splice variant is expressed \~1,800-fold higher in metastatic MDA-MB-231 cells than in weakly metastatic MCF-7 cells. When voltage-gated membrane currents are examined in different cell lines, inward currents only occur in the highly metastatic breast cancer cell line MDA-MB-231 ([@B37]). *In vivo*, it is widely acknowledged that Nav1.5 is present in breast cancer biopsies and is related to lymph node metastasis ([@B37]). *SCN5A* expression is significantly elevated in breast cancer tissues and is an independent predictor of poor prognosis compared to its expression in normal breast tissue. *SCN5A* is overexpressed in tumor samples from patients who experience recurrence and death within 5 years; thus, *SCN5A* overexpression is associated with increased odds of developing metastasis ([@B104]). Nelson and his colleagues investigated the functional activity of Nav1.5 and its specific contribution to breast cancer tumor progression. *SCN5A* is upregulated at the mRNA and protein levels in metastatic breast tumors compared to that in normal, non-cancerous tissue ([@B72]; [@B73]; [@B101])

Furthermore, some factors affect Nav1.5 expression in breast cancer cells. The β1 subunit mRNA and protein are strongly expressed in MCF-7 cells and are barely detectable in MDA-MB-231 cells. Inhibition of the β1 subunit reduces adhesion and enhances metastatic cell behavior by upregulating nNav1.5 expression ([@B27]). It has been reported that the expression level of repressor element silencing transcription factor (REST) is significantly lower in MDA-MB-231 cells than in MCF-7 cells ([@B56]). The inhibition of REST results in re-expression of various neonatal genes ([@B59]), and REST recruits histone deacetylases (HDACs) for transcriptional repression activity ([@B85]). It has been postulated that downregulation of REST and HDAC2 expression levels enhances the expression of Nav1.5 and nNav1.5, promoting aggressiveness of tumors ([@B56]). The sigma-1 receptor is known as a protein located on the plasma membrane, endoplasmic reticulum, and perinuclear areas ([@B47]; [@B48]), and is up-regulated in breast cancer cells and tissues ([@B8]). In breast cancer cells, the sigma-1 receptor combines with nNav1.5 protein to form a complex with a four-fold symmetry ([@B9]), which translocate nNav1.5 protein to the plasma membrane, thereby increases the metastatic activity ([@B8]). Salt-inducible kinase 1 (SIK1) has been identified as an important factor in regulating sodium homeostasis and as a tumor repressor that participates in the progression of cancer cells ([@B88]; [@B87]). Lower expression of SIK1 was observed in different breast tumor grades than in normal tissues ([@B43]). Silencing SIK1 upregulates *SCN5A* expression and increases H^+^ outflow, thus, improving invasiveness ([@B43]). TGF-β1 is a well-known inducer of epithelial-to-mesenchymal transition (EMT) and a multifunctional regulatory factor affecting cancer development ([@B55]; [@B70]). Weakly metastatic MCF-7 cells treated with TGF-β1 demonstrated increased expression of *SCN5A* and induction of invasion ([@B43]). Epidermal growth factor (EGF) signals have been confirmed to be overexpressed and are involved in the development of breast cancer ([@B1]; [@B106]). Treatment with EGF promoted the migratory capacity of MDA-MB-231 cells by increasing the functional expression of the Nav1.5 channel ([@B42]). These results confirm that Nav1.5 channels play an important role in human breast cancer by affecting metastatic activity.

Furthermore, the importance of Nav1.5 expression in human breast cancer cells for the colonization of organs was assessed. ShCTL or shNav1.5 breast cancer cells injected into mice. ShCTL cells expressing Nav1.5 strongly colonized and invaded the chest area. All mice showed lung colonization and some showed rachis and rib colonization ([@B32]). In addition, a high level of nNav1.5 expression is associated with the estrogen receptor (ERα) status of breast cancer. In all cases, lack of ERα was positive for nNav1.5 expression. In all cases of negative nNav1.5 expression, ERα is present ([@B101]). It is widely acknowledged that breast cancer cases lacking ERα protein are closely related to a more advanced stage and have a worse prognosis ([@B109]; [@B112]). This is consistent with previous results showing that a high level of nNav1.5 expression is associated with aggressive breast cancer development. Consequently, nNav1.5 expression enhances growth and metastatic dissemination of breast cancer and is a potential prognostic marker for breast cancer.

Mechanisms of Action {#s1_2}
--------------------

Metastasis of breast cancer is a complex process, and there are a considerable number of studies focusing on this topic. Nav1.5 is involved in the metastatic cascade in breast cancer by acting on different targets.

Na^+^ currents carried by Nav1.5 have been found to promote the invasiveness of the breast cancer cell line MDA-MB-231 by regulating the H^+^ influx carried through Na^+^/H^+^ exchanger isoform-1 (NHE-1). NHE-1, which is an important regulator of H^+^ efflux, is co-expressed with Nav1.5 in lipid rafts within the caveolae of MDA-MB-231 cells. NHE-1 and Nav1.5 are coupled in the metastatic process of MDA-MB-231 cells ([@B19]). Na^+^ inward currents can be found in highly metastatic MDA-MB-231 cells but are absent in weakly metastatic or normal cells. Similarly, highly metastatic MDA-MB-231 cells express a high level of NHE-1 mRNA, while weakly metastatic MCF-7 cells express a low level of NHE-1 mRNA, and normal cells express no NHE-1 ([@B25]). In MDA-MB-231 cells, Nav1.5 allosterically modulates the activity of NHE-1, rendering NHE-1 more active at physiological intracellular pH. This results in increased H^+^ efflux to the extracellular space, leading to acidification of the peri-membrane and intracellular alkalization ([@B20]; [@B4]). The environment of the perimembrane favors the proteolytic activity of cysteine cathepsins (Cat) and matrix metalloproteinases (MMPs), which are major drivers of extracellular matrix (ECM) degradation and increase the invasiveness of breast cancer cells ([**Figure 1**](#f1){ref-type="fig"}). Cat C, Cat B, Cat K, and Cat L are involved in Cat-dependent invasiveness in MDA-MB-231 cells. Apart from Cat K, the activity of this proteolytic protein can be potentiated by Nav1.5 ([@B40]; [@B84]). NHE-1--modulated invasiveness can also be found in hepatoma cells ([@B103]).

![Nav1.5 promotes the activity of NHE-1, resulting in the acidification of the peri-membrane, which favors the proteolytic activity of Cat and MMPs **(yellow line)**. Nav1.5 also promotes invasiveness by the CD44-src-cortactin signaling pathway. After phosphorylation, cortactin releases actin-severing cofilin, promoting the formation of actin barbed ends of invadopodia **(red line)**. Overexpression of CD44 upregulates the expression and activity of NHE-1, resulting in the expression level of MMPs (MMP2, MMP9, and MMP14) by increasing phosphorylated ERK1/2 **(black line)**. Nav1.5 dependent Vm depolarization regulates Rac1 activation by its interaction with phosphatidylserine **(blue solid line)**. Rac1 regulates the Arp2/3 complex and is closely associated with phosphorylation of cortactin and cofilin, promoting the promigratory phenotype **(blue dotted line)**. High expression of Na~V~1.5 induces expression of SNAI1, triggering the EMT and pro-metastatic effect of breast cancer cells **(purple line)**. (Dotted line indicates that the mechanism exists but has not been confirmed in breast cancer).](fphar-11-01111-g001){#f1}

Nav1.5 expression enhances src kinase activity and controls cortactin phosphorylation, resulting in the release of actin-severing cofilin and the formation of actin barbed ends of invadopodias, which are actin-rich organelles that enable cells to stretch into the ECM and perform their proteolytic effect ([@B76]; [@B20]). It is known that Nav1.5 expression in breast cancer cells is closely associated with the protein level of CD44, which correlates with poor outcomes of breast cancer ([@B65]; [@B73]). In turn, CD44 adheres to its ligand and leads to the activation of src and phosphorylation of cortactin ([@B14]; [@B50]), thus, supporting that Nav1.5 may potentiate the invasion of breast cancer cells by the CD44-src-cortactin signaling axis. Apart from the CD44-src-cortactin signaling axis, CD44 targets NHE-1 to regulate the metastatic capacities of MDA-MB-231 cells through the mitogen-activated protein kinase pathway. Overexpression of CD44 upregulates the expression and activity of NHE-1, resulting in the increased expression of MMPs (MMP2, MMP9, and MMP14) by increasing phosphorylated ERK1/2 ([**Figure 1**](#f1){ref-type="fig"}). Moreover, CD44 accelerates tumor growth and metastasis to the lung in MDA-MB-231 cells ([@B23]).

Increasing evidence shows that plasma membrane potential (Vm) is related to cell cycle progression and the level of differentiation, development, regeneration, and migration of cancer cells ([@B92]; [@B102]). Emerging evidence confirms that proliferating tumor cells depolarizes Vm, while terminally differentiated non-cancer cells are characterized by hyperpolarized Vm ([@B12]; [@B63]; [@B37]). Yang et al. reported that a steady-state inward Na^+^ current carried by Nav1.5 contributes to depolarizing the resting Vm in MDA-MB-231 cells ([@B105]). Previous studies suggest that Vm depolarization promotes the redistribution of anionic phospholipids PIP~2~ and phosphatidylserine within the plasma membrane, resulting in GTPase K-Ras activation ([@B24]; [@B113]; [@B83]). Rac1 is one of the Rho GTPases that contribute to lamellipodia formation and migration ([@B74]; [@B90]). Similarly, Nav1.5 dependent Vm depolarization regulates Rac1 activation and localization in lamellipodia by its interaction with phosphatidylserine, regulating cell morphology and migration in breast cancer cells ([@B105]). Rac1 is a potential upstream regulator of the Arp2/3 complex, which is required for lamellipodia extension ([@B93]). Furthermore, Rac1 is closely associated with phosphorylation of cortactin and cofilin, promoting the acquisition of a promigratory phenotype ([@B49]; [@B91]) ([**Figure 1**](#f1){ref-type="fig"}).

Na^+^ currents carried by Nav1.5 stimulate phosphorylation of protein kinase A (PKA), which increases the Nav1.5 mRNA level but does not affect the total protein level. This changes the distribution of Nav1.5 in MDA-MB-231 cells, with the level of Nav1.5 increased on the plasma membrane and reduced in cytoplasm. The externalization of Nav1.5 potentiates the invasion and migration of breast cancer cells. The increase of Nav1.5 on the membrane in turn increases the Na^+^ currents, thus, forming a positive feedback ([**Figure 2**](#f2){ref-type="fig"}) ([@B28]). There is also positive feedback between Nav1.5 and GTPase RhoA, which is overexpressed in many cancers, including breast cancer. Silencing of RhoA decreases the expression of Nav1.5 mRNA, as well as Nav1.5-mediated Na^+^ currents. In turn, silencing of Nav1.5 decreased the protein level of RhoA ([@B33]), which may be a result of the reduction in calcium concentration ([@B81]). In addition, suppressing both RhoA and Nav1.5 significantly reduced the invasion of MDA-MB-231 cells ([@B33]).

![Na^+^ currents carried by Nav1.5 stimulate phosphorylation of PKA, which increases the Nav1.5 mRNA level but does not affect the total protein level. This changes the distribution of Nav1.5 in MDA-MB-231 cells, such that Nav1.5 protein level increases on the membrane but that in the cytoplasm decreases. The externalization of Nav1.5 then potentiates the invasion and migration of breast cancer cells. The increase of Nav1.5 on the membrane in turn increases the Na^+^ currents, thus, forming a positive feedback.](fphar-11-01111-g002){#f2}

Recent research has shown that Nav1.5 promotes invasiveness by taking part in EMT, a process involved in tissue formation during embryogenesis and repair processes, and promoting cancer cell dissemination from the primary tumor ([@B10]). MDA-MB-231 cells present typical spindle-shaped mesenchymal morphology and multiple filopodia. Upon knocking down the expression of *SCN5A*, these cells show decreased the number of filopodia that are shorter in length. The expression level of SNAI1, an EMT-inducing transcription factor, significantly decreased in MDA-MB-231 cells treated with a specific small-hairpin RNA (shNav1.5 cells). In contrast, MCF-7 cells overexpressing Nav1.5 display an increased invasive capacity, as well as an increased expression level of SNAI1, which provides evidence for the role of SNAI1 in Nav1.5 activity-mediated invasive process of breast cancer. Indeed, loss of expression of SIK1 upregulates Nav1.5 activity and expression ([@B43]). Hence, it is that low expression levels of SIK1 in breast cancer cells induce the activity and expression of Nav1.5, followed by high expression of SNAI1, triggering the EMT and metastasis observed in breast cancer cells.

Inhibitors of Nav1.5 {#s1_3}
--------------------

Nowadays, a variety of approaches, including specific antibodies, natural toxins, and pharmacological agents, are applied to reduce the metastasis of breast cancer cells by inhibiting Nav1.5 ([**Table 1**](#T1){ref-type="table"}).

###### 

Inhibitors of Nav1.5.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Inhibitor     Type                                     Effects on cancer cells                  Mechanism                                                                                                  References
  ------------- ---------------------------------------- ---------------------------------------- ---------------------------------------------------------------------------------------------------------- ------------
  NESOpb/E3Ab   Antibodies                               Reduce migration and invasion            Specifically inhibit Na~V~1.5                                                                              [@B17]\
                                                                                                                                                                                                             [@B39]

  Phenytoin     Antiarrhythmic and antiepileptic agent   Reduce mobility migration and invasion   Inhibit Na+ currents\                                                                                      [@B104]\
                                                                                                  down-regulate EGF expression and ERK1/2 phosphorylation\                                                   [@B67]\
                                                                                                  reduce activity of MP-7, cathepsin E and kallikrein-10                                                     [@B72]

  DAPT          Notch signal inhibitor                   Reduce proliferation\                    Increase the level of Notch4mRNA and decreased the ratio of MMP9 to TIMP1                                  [@B2]
                                                         lateral motility                                                                                                                                    

  DHA           ω-3 LC-PUFA                              Reduce migration and invasion            Inhibit the expression of PPARβ and downregulate SCN5A expression and activity of NHE-1                    [@B54]\
                                                                                                                                                                                                             [@B97]

  Ranolazine    Antiarrhythmic drug                      Reduce invasion                          Decreases Na+ influx and ECM degradative activity                                                          [@B32]

  Taxol         Anticancer drug                          Decrease invasion                        Left shift of Na~V~1.5 activation and affect microtubule polymerization                                    [@B94]

  FS50          Animal salivary protein                  Reduce migration and invasion            Decrease the expression of Na~V~1.5 mRNA level and distribution of Na~V~1.5 protein in the cell membrane   [@B111]

  Compounds     Synthetic substances                     Reduce the invasion                      Block Nav1.5 channel                                                                                       [@B34]

  Propranolol   β‐AR blocker                             Reduce migration and invasion            Affect the properties and expression of Nav1.5                                                             [@B60]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Application of an anti-peptide polyclonal antibody, NESOpAb, blocks VGSC currents of EBNA-293 cells transfected with nNav1.5 and has no significant effect on adult Nav1.5 transfectants; thus, NESOpAb specifically targets nNav1.5, but not adult Nav1.5 ([@B26]). NESOpAb inhibits the migration and invasion of MDA-MB-231 cells by suppressing the functional nNav1.5 activity but does not show similar results in human metastatic prostate cancer PC-3M cells, in which Nav1.7 is dominant ([@B30]; [@B17]), which is consistent with the notion that NESOpAb specifically recognizes nNav1.5. E3Ab is a peptide-specific polyclonal antibody that recognizes the third extracellular region of Nav1.5, leading to specific inhibition of Nav1.5 activity ([@B99]). MDA-MB-231 cells treated with E3Ab show significantly decreased migration and invasive abilities. Indeed, a marked anti-proliferative effect was observed in E3Ab-treated MDA-MB-231 cells ([@B39]).

Phenytoin is an antiarrhythmic and antiepileptic agent that shows a high affinity toward Nav1.5 on the membrane of metastatic breast cancer cells in its inactivated state and reduces Na^+^ currents. The depolarization of MDA-MB-231 causes the opening of VGSCs, which then rapidly enter an incomplete inactivated state after a few milliseconds. This process produces transient and persistent Na^+^ currents, which play a key role in the metastasis of breast cancer cells ([@B104]). Phenytoin significantly reduces the mobility, migration, and invasion of metastatic breast cancer *in vitro* and *in vivo* ([@B72]; [@B67]). Blocking the Na^+^ current by phenytoin results in the downregulation of EGF expression and EGF-induced ERK1/2 phosphorylation, reducing the activity of MMP7, cathepsin E, and kallikrein-10, among which phenytoin showed the greatest inhibitory effect on cathepsin E ([@B67]). It has been proven that higher cathepsin E levels in the serum are positively correlated with poorer clinical prognosis in breast cancer patients ([@B58]), thus, phenytoin might serve as an effective drug for improving therapeutic efficiency and survival of patients ([@B67]). Although phenytoin does not affect proliferation *in vitro* ([@B104]), it reduces the proliferation of metastatic breast cancer and slows tumor growth *in vivo* ([@B72]). The Notch signal inhibitor *N*-\[*N*-(3,5-difluorophenacetyl)-[l]{.smallcaps}-alanyl\]-*S*-phenylglycine-*t*-butyl ester (DAPT) has an anti-proliferative effect on MDA-MB-231 cells that can be decreased by phenytoin. Both DAPT and phenytoin reduce the lateral motility of breast cancer cells. It is reasonable to speculate that they have different effects on the proliferation of breast cancer cells. DAPT reduces the nNav1.5 mRNA expression level, which is not observed in the phenytoin treatment group. DAPT significantly reduces the ratio of MMP9 to tissue inhibitor of metalloproteinases-1 (TIMP1), which could be partly reversed by the combination of DAPT and phenytoin, indicating that the application of DAPT together with phenytoin is not a better choice than the single treatment of DAPT and phenytoin ([@B2]). Furthermore, phenytoin inhibits the metastasis of breast cancer cells to other organs such as the lungs, liver, and spleen by reducing the density of MMP9-expressing cells ([@B72]). This suggests that the contribution of Nav1.5 to tumor growth *in vivo* is closely associated with adjacent tissues or the ECM.

It is noteworthy that some dietary habits have been shown to protect against cancer. It has been reported that omega-3 long-chain polyunsaturated fatty acids (ω-3 LC-PUFAs) play a role in the prevention of cancer. The effects of docosahexaenoic acid (DHA), one of the most important ω-3 LC-PUFAs, have been studied in the field of breast cancer. Short- and long-term applications of DHA inhibit nNav1.5 activity in the metastatic human MDA-MB-231 breast cancer cell line by decreasing the peak VGSC current density. In the long-term application, DHA inhibits both mRNA and protein expression levels of nNav1.5 and reduces cell migration ([@B54]). Peroxisome proliferator-activated receptor β (PPARβ) regulates the expression of numerous genes, including *SCN5A*, by binding with PPAR response elements on the promoters of these genes, thus, regulating cell survival, inflammation, and metabolism ([@B78]). DHA, a natural ligand of PPAR, has shown the potential to suppress tumor growth in different kinds of models with no side effects ([@B36]; [@B107]). DHA has been shown to reduce PPARβ expression, which is overexpressed in breast cancer cells, and inhibits the invasiveness and growth of breast cancer cells ([@B96]; [@B107]; [@B97]). The downregulation of PPARβ reduces *SCN5A* expression at both the mRNA and protein levels, as well as nNav1.5 density at the plasma membrane, which finally leads to the reduction of Na^+^ currents. In addition, the downregulation of PPARβ reduces NHE-1--dependent H^+^ efflux by inhibiting the activity of Nav1.5 channels without altering NHE-1 expression. PPARβ is indispensable for DHA to reduce Nav1.5 expression and NHE-1 activity, giving rise to the invasiveness of breast cancer cells ([@B97]).

Ranolazine has been approved by the US Food and Drug Administration for chronic angina ([@B5]). One of the most characterized pharmacological effects of ranolazine is its ability to selectively inhibit late Na^+^ currents. The inhibition of Na^+^ currents triggers a steeper Na^+^ gradient and activation of the Na^+^/Ca exchanger, which reduces the intracellular overloaded calcium and improves ventricular relaxation in cardiac ischemia conditions ([@B38]). Ranolazine has also been shown to have anti-invasiveness potential in breast cancer. *In vitro*, ranolazine reduces the function of Nav1.5 and decreases Na^+^ influx in MDA-MB-231 cells, which results in decreased ECM degradative activity and pro-invasive morphology of cells. *In vivo*, ranolazine slows down tumor growth and inhibits the colonization of breast cancer cells to other organs without obvious toxic effects by reducing the Nav1.5 carried currents in tumor tissues ([@B32]). The expressions of β‐adrenergic receptor (β‐AR) and Nav1.5 overlap substantially in MDA-MB-231 cells. Propranolol which is a blocker of β‐AR, coupled to with PKA activation, modulates Nav1.5 and takes part in reducing migration and invasion of MDA-MB-231 cells. Short-term treatment with propranolol tends to reduce peak Na^+^ currents carried by Nav1.5, while long-term treatment results in sustained changes of properties and expression of Nav1.5. Indeed, the role of factors contained in the serum cannot be ignored. Both propranolol and ranolazine reduced the motility and invasiveness of MDA-MB-231 cells, but the effect of their combination was not better than that of individual treatments ([@B60]).

Taxol and its derivatives, such as docetaxel, are widely used in the treatment of breast cancer ([@B29]). The widely accepted explanation for their effects is that they stabilize the microtubules during mitosis, which leads to the inhibition of cell division ([@B21]). Taxol also has a potential anti-invasive effect on breast cancer cells at low concentrations but has no effect on cell proliferation. The reduction of the current carried by Nav1.5 was not observed in cells pretreated with taxol, which demonstrates a significant leftward shift of the activation properties of Nav1.5. It is known that the activity of sodium channels is closely associated with perturbation of microtubules ([@B69]). Tran reported that a short-term and low-dose taxol treatment is sufficient to affect microtubule polymerization ([@B94]). It seems that the effects of taxol on cell invasiveness are complicated, and other proteins involved in the Nav1.5-regulated signaling pathway may be regulated by taxol, but the precise mechanisms remain unknown.

Recently, animal peptides have drawn considerable interest. FS50, the salivary protein from *Xenopsylla cheopis*, shows an inhibitory effect against the Nav1.5 channel ([@B100]). FS50 significantly reduced the peak VGSC currents and decreased the expression of Nav1.5 mRNA in MDA-MB-231 cells but had no effect on the total Nav1.5 protein levels. Notably, FS50 reduces the Nav1.5 protein expression in the plasma membrane, which means that FS50 only changes the distribution of the protein between the plasma membrane and the cytoplasm. The effect is identical to the effects of a PKA inhibitor; thus, FS50 may inhibit the PKA pathway, resulting in the reduced expression of Nav1.5. In the future, it is worth detecting PKA-related proteins after the treatment of FS50 ([@B15]; [@B28]). FS50 inhibits the migration and invasion of MDA-MB-231 cells but has no effect on the proliferation of MCF-7 and MDA-MB-231 cells. The reduction of MMP9 activity and the ratio of MMP9 mRNA to TIMP1 mRNA were observed in MDA-MB-231 cells treated with FS50 ([@B111]).

In addition to the known VGSC-blocking drugs, scientists have developed a highly predictive and comprehensive three-dimensional quantitative structure--activity relationship model for designing the compounds to bind with VGSC ligands ([@B110]). Five low micromolar, small molecule compounds acting as Nav1.5 blockers in MDA-MB-231 cells were designed, synthesized, and evaluated. Two of the compounds were identified to reduce peak Na^+^ currents and reduce the invasion of MDA-MB-231 cells without affecting cell viability ([@B34]). Compared with known drugs, these compounds are more effective and have simpler chemical structures. Moreover, synthetic substances are designed to target Nav1.5, providing a new and potent direction to develop drugs for the treatment of breast cancer metastasis.

The membrane current generated by VGSCs has two distinct modes: transient (I~NaT~) and persistent (I~NaP~). I~NaP~ can last 100 ms to 1 s, while I~NaT~ lasts a millisecond ([@B31]). Hypoxia, which is commonly observed in cancer and promotes metastasis and invasion, significantly contributes to increasing I~NaP~ ([@B46]; [@B71]; [@B80]; [@B45]). Compared with I~NaT~, I~NaP~ is resistant to inactivation even at depolarized potentials and will lead to significant changes in the global level of Na^+^ that affect Nav1.5-dependent mechanisms and play an important role in cancer progression ([@B86]). Indeed, the inhibition of I~NaP~ has been shown to produce a major anti-metastatic effect and has been proposed as a new target ([@B45]). As mentioned above, MDA-MB-231 cells exhibit depolarized Vm. In addition, slower kinetics of activation, inactivation, and recovery from inactivation are observed in nNav1.5 than in the 'adult' form ([@B75]). Thus, it is reasonable to assume that I~NaP~ is mainly responsible for Na^+^ elevation in breast cancer cells. At present, it is easy to identify I~NaT~ and I~NaP~ by whole-cell patch-clamp recordings, and a number of pharmacological agents have been shown to selectively block I~NaP~ ([@B95]; [@B61]). In the future, additional I~NaP~ blockers inhibiting Nav1.5-mediated persistent current should be considered as a new target to reduce metastasis of breast cancer. In addition, most agents listed above produce a major anti-metastatic effect by decreasing the current carried by Nav1.5 or changing the properties of Nav1.5. Specifically, decreasing the expression of nNav1.5 is another ideal target for specific anti-breast cancer treatment.

Perspectives {#s2}
============

The increasing evidence is indicative of the role of aberrant Nav1.5 activation in the metastatic progression of breast cancer cells. Nav1.5 functions to trigger a variety of downstream mechanisms in breast cancer cells to regulate metastatic and invasive capacity. Considering the large and growing body of evidence, different approaches recognizing Nav1.5 are applied to inhibit metastasis of breast cancer *in vitro* and favor Nav1.5 as an anti-metastatic target. Although we reviewed several studies here, there are many unanswered questions that require further investigation: (i) Is it possible to make nNav1.5 a biomarker of early diagnosis of breast cancer; (ii) Can we develop additional agents specifically blocking I~NaP~ or nNav1.5 to improve efficacy and reduce side effects; and (iii) How can we accumulate the process of translational medicine and promote the application of these agents in the clinic to improve the outcomes for breast cancer patients.
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